+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

European Geriatric Medicine Market 2020-2026

  • PDF Icon


  • October 2020
  • Region: Europe
  • Orion Market Research Private Limited
  • ID: 5240926
European Geriatric Medicine Market Size, Share & Trends Analysis Report by Therapeutic (Analgesic, Anticoagulant, Antihypertensive, Antidiabetic, and Others) and by Condition (Cardiovascular Diseases (CVDs), Diabetes, Neurological, Cancer, Respiratory, and Others) and Forecast 2020-2026.

The European geriatric medicine market is projected to witness considerable growth of 5.4% during the forecast period. The major factors contributing to the growth of the market include the increasing geriatric population in the Western European economies, such as Italy. Moreover, the high spending on healthcare facilities with the significant presence of key market players are other factors propelling the market growth in the region. UK has one of the most developed healthcare infrastructures for elderly people, owing to which, the market is growing at a considerable rate in the European region.

The geriatric medicine market is classified on the basis of therapeutics and conditions. Based on therapeutics, the market is segmented into analgesic, anticoagulant, antihypertensive, antidiabetic, and others. Based on the condition, the market is segregated into CVDs, diabetes, neurological, cancer, respiratory, and others. Among these conditions, the CVDs segment contributes significantly to the market. The significant contribution of the segment is backed by the significant patient pool of CVDs across the globe. With the rise in age, the development of CVDs increases subsequently. Therefore, a huge market is covered by CVDs medicines in the geriatric medicine market.

Geographically, the European geriatric medicine market is segmented into Germany, UK, France, Italy, Spain, and the rest of Europe. UK contributed a significant share in the European geriatric medicine market. The growth is owing to the various healthcare facilities and well-developed healthcare infrastructure for the geriatric population. Further, Germany and France have a world-class healthcare system providing a stable platform for the growth of the geriatric medicine market in the respective countries. Apart from the major European countries, Switzerland, the Netherlands, Denmark, Norway Ireland, Hungary, and Belgium are some other countries of Europe that are providing a significant contribution to the growth of the geriatric medicine market in the region.

The European geriatric medicine market is influenced by product development and advancements conducted by the market players. Some of the global key players of the geriatric medicine market include Novartis AG, GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Merck & Co. Inc., Sanofi SA, Pfizer Inc., Johnson & Johnson Services Inc., and AstraZeneca PLC. These players are playing a significant role in the growth of the geriatric medicine market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.

Research Methodology

The market study of the European geriatric medicine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. the team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog
The report is intended for drug manufacturers, pharmaceutical & biopharmaceutical companies, research institutes, academic institutes, industry associates & experts, government organizations, regulatory bodies, and other market participants for overall market analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. European Geriatric Medicine Market Research and Analysis by Therapeutics
2. European Geriatric Medicine Market Research and Analysis by Condition

The Report Covers:
  • Comprehensive research methodology of the European geriatric medicine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the European geriatric medicine market.
  • Insights about market determinants which are stimulating the European market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities
4. Market Segmentation
4.1. European Geriatric Medicine Market by Therapeutic
4.1.1. Analgesic
4.1.2. Anticoagulant
4.1.3. Antihypertensive
4.1.4. Antidiabetic
4.1.5. Others (Statins and Antipsychotic)
4.2. European Geriatric Medicine Market by Condition
4.2.1. Cardiovascular Diseases (CVDs)
4.2.2. Diabetes
4.2.3. Neurological
4.2.4. Cancer
4.2.5. Respiratory
4.2.6. Others (Arthritis and Osteoporosis)
5. Regional Analysis
5.1. UK
5.2. Germany
5.3. France
5.4. Spain
5.5. Italy
5.6. Rest of Europe
6. Company Profiles
6.1. Abbott Laboratories Inc.
6.1.1. Overview
6.1.2. Abbott Laboratories in Europe
6.1.3. Abbott Laboratories in Geriatric Medicine Landscape
6.1.4. Recent Developments
6.2. Amgen Inc.
6.3. Astellas Pharma Inc.
6.4. AstraZeneca PLC
6.5. Boehringer Ingelheim GmbH
6.6. Bristol-Myers Squibb Co.
6.7. Cipla Ltd.
6.8. Eli Lilly and Co.
6.9. GlaxoSmithKline PLC
6.10. Johnson & Johnson Services Inc.
6.11. Merck & Co., Inc.
6.12. Novartis AG
6.13. Pfizer Inc.
6.14. Sanofi SA
6.15. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Eli Lilly and Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.